Novel HDGF/HIF-1\u03b1/VEGF axis in oral cancer impacts disease prognosis

Yu-Wei Lin,Shih-Chung Huang,Ming-Hong Tai,Shih-Tsung Huang,Jian-Ching Wu,Tian-Huei Chu,Ching-Chih Lee

doi:10.1186/s12885-019-6229-5

Abstract

BackgroundHepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer. The current study was designed to elucidate the regulatory mechanism between HDGF and vascular endothelial growth factor (VEGF) and the clinical impact of oral cancer.MethodsTCGA data and surgical samples from oral cancer patients were used for the clinicopathological parameter and survival analysis. Human oral cancer SCC4 and SAS cells were treated with recombinant HDGF protein. VEGF gene expression and protein level were analyzed by RT-PCR, Western blotting, and enzyme-linked immunosorbent assay. The signaling pathways for regulating VEGF expression were investigated. The nucleolin neutralizing antibody and HIF-1α inhibitor were applied to SCC4 cells to investigate their effects on the HDGF-stimulated VEGF pathways.ResultsTCGA and immunohistochemical analysis revealed a positive correlation between HDGF and VEGF expression in oral cancer tissues. Recombinant HDGF significantly increased VEGF gene and protein expression in oral cancer SCC4 cells in a dose-dependent manner. HDGF enhanced the phosphorylation levels of AKT and IkB and the protein level of HIF-1α and NF-κB. The nucleolin-neutralizing antibody abolished HDGF-stimulated HIF-1α, NF-κB and VEGF protein expression in SCC4 cells. The HIF-1α inhibitor antagonized the HDGF-induced VEGF gene expression. High VEGF expression was strongly correlated with HDGF expression, advanced disease, and poor survival.ConclusionThis study postulated a new pathway in which HDGF activated HIF-1α and then induced VEGF expression through binding to membrane nucleolin under normoxic conditions, leading to poor disease control. The HDGF/HIF-1α/VEGF axis is important for developing future therapeutic strategies.

Highlights

Hepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer
Correlation of HDGF and vascular endothelial growth factor (VEGF) expression and clinicopathological parameters in oral cancer tissues Because HDGF overexpression is correlated with angiogenesis and tumorigenesis, including in oral cancer [26], we investigated whether there was a relationship between HDGF and VEGF expression in oral cancer and head and neck cancer
RT-PCR showed that exogenous HDGF protein significantly increased VEGF gene expression by HDGF stimulates AKT/Hypoxia-inducible factor 1-α (HIF-1α)/NF-κB signaling in oral cancer cells Given the well-known signaling pathways for regulating VEGF expression [27, 28], we focused on the activation of specific transcription factors, including HIF-1α, NF-κB, and STAT3

Summary

Introduction

Hepatoma-derived growth factor (HDGF) participates in angiogenesis and represents a negative prognostic factor in oral cancer. The current study was designed to elucidate the regulatory mechanism between HDGF and vascular endothelial growth factor (VEGF) and the clinical impact of oral cancer. Oral cancer is characterized by its aggressive behavior. Even after radical surgery followed by adjuvant radiotherapy and chemotherapy, the survival rate of oral. Angiogenesis is required for tumor growth [3] and facilitates tumor recurrence and metastasis [4, 5] through perturbing the balance of proangiogenic and antiangiogenic factors. Vascular endothelial growth factor (VEGF) is the most important one [6]. Understanding angiogenesis, the VEGF pathway, is urgently needed for the risk stratification of oral cancer patients and the development of novel therapeutic targets.

Methods

Results

Conclusion